Iron-chelation therapy with oral chelators in patients with thalassemia major

Hematology

Volumn 18, Issue 1, 2013, Pages 50-55

  Uygun, Vedat ^a   Kurtoglu, Erdal ^a  

^a Antalya Egitim ve Arastirma Hastanesi   (Turkey)

Author keywords

Oral chelator; Side effects; Splenectomy; Thalassaemia major

Indexed keywords

CHELATING AGENT; DEFERASIROX; DEFERIPRONE; FERRITIN;

ADULT; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEARING; HEARING DISORDER; HUMAN; HYPERSPLENISM; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SIDE EFFECT; SPLENECTOMY; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT RESPONSE; VISION; VISUAL DISORDER;

ADOLESCENT; ADULT; BENZOATES; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; MIDDLE AGED; PYRIDONES; RETROSPECTIVE STUDIES; SPLENECTOMY; TRIAZOLES; YOUNG ADULT;

EID: 84873519235     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000046     Document Type: Article

References (27)

1. Wintrobe MM, Greer JP. Wintrobe's clinical hematology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009. pp. 1099-100.
2. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci. 2010;1202:1-9.
3. Canatan D, Kose MR, Ustundag M, Haznedaroglu D, Ozbas S. Hemoglobinopathy control program in Turkey. Community Genet. 2006;9:124-6.
4. Neufeld EJ. Update on iron chelators in thalassemia. Hematol Am Soc Hematol Educ Program 2010;2010:451-5.
5. Cianciulli P. Iron chelation therapy in thalassemia syndromes. Mediterr J Hematol Infect Dis. 2009;1:e2009034.
6. Chua-anusorn W, Macey DJ, Webb J, de la Motte Hall P, St Pierre TG. Effects of prolonged iron loading in the rat using both parenteral and dietary routes. Biometals 1999;12:103-13.
7. Fischer R, Tiemann CD, Engelhardt R, Nielsen P, Durken M, Gabbe EE, et al. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. Am J Hematol. 1999;60:289-99.
8. Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, et al. Pharmacokinetics of deferiprone in patients with beta-thalassaemia: impact of splenectomy and iron status. Clin Pharmacokinet. 2011;50:41-50.
9. Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 2007;3:795-805.
10. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 2008;32:1-15.
11. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91: 873-80.
12. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28:196-208.
13. Hoffbrand AV, Al-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91: 295-300.
14. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:557-66.
15. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011;118:884-93.
16. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73:403-9.
17. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusiondependent anaemia and iron overload. Br J Haematol. 2009; 147:752-9.
18. Cassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L, Graziadei G, et al. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. AnnHematol.2012;91(9):1443-9.
19. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. Hemoglobin 2011;35:186-98.
20. Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 2012;119: 2746-53.
21. Meerpohl JJ, Antes G, Rucker G, Fleeman N, Motschall E, Niemeyer CM, et al. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev. 2012;2:CD007476.
22. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008;111:583-7.
23. Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, et al. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos. 2008;36:2523-38.
24. Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf. 2007;6:235-9.
25. Singh S, Epemolu RO, Dobbin PS, Tilbrook GS, Ellis BL, Damani LA, et al. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos. 1992;20:256-61.
26. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108:305-12.
27. Piperno A. Classification and diagnosis of iron overload. Haematologica 1998;83:447-55.